Actinium Pharmaceuticals Future Growth
Future criteria checks 5/6
Actinium Pharmaceuticals is forecast to grow earnings and revenue by 68.1% and 58.1% per annum respectively while EPS is expected to grow by 67.3% per annum.
Key information
68.1%
Earnings growth rate
67.3%
EPS growth rate
Biotechs earnings growth | 23.2% |
Revenue growth rate | 58.1% |
Future return on equity | n/a |
Analyst coverage | Good |
Last updated | 29 Apr 2024 |
Recent future growth updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 142 | 56 | -6 | 2 | 5 |
12/31/2025 | 63 | -7 | -45 | -50 | 6 |
12/31/2024 | N/A | -45 | -76 | -49 | 5 |
3/31/2024 | 0 | -46 | -40 | -40 | N/A |
12/31/2023 | 0 | -49 | -47 | -47 | N/A |
9/30/2023 | N/A | -50 | -48 | -48 | N/A |
6/30/2023 | 0 | -46 | -42 | -42 | N/A |
3/31/2023 | 0 | -39 | -1 | -1 | N/A |
12/31/2022 | 1 | -33 | 8 | 9 | N/A |
9/30/2022 | 1 | -30 | 11 | 11 | N/A |
6/30/2022 | 1 | -27 | 11 | 11 | N/A |
3/31/2022 | 1 | -25 | -21 | -21 | N/A |
12/31/2021 | 1 | -25 | -21 | -21 | N/A |
9/30/2021 | 1 | -23 | -22 | -22 | N/A |
6/30/2021 | 1 | -22 | -22 | -21 | N/A |
3/31/2021 | 1 | -22 | -22 | -21 | N/A |
12/31/2020 | N/A | -22 | -22 | -22 | N/A |
9/30/2020 | N/A | -20 | -20 | -20 | N/A |
6/30/2020 | N/A | -21 | -21 | -21 | N/A |
3/31/2020 | N/A | -22 | -22 | -22 | N/A |
12/31/2019 | N/A | -22 | -22 | -21 | N/A |
9/30/2019 | N/A | -24 | -21 | -21 | N/A |
6/30/2019 | N/A | -23 | -22 | -22 | N/A |
3/31/2019 | N/A | -23 | -21 | -21 | N/A |
12/31/2018 | N/A | -24 | -21 | -21 | N/A |
9/30/2018 | N/A | -22 | -20 | -19 | N/A |
6/30/2018 | N/A | -23 | -19 | -19 | N/A |
3/31/2018 | N/A | -25 | -22 | -22 | N/A |
12/31/2017 | N/A | -27 | N/A | -22 | N/A |
9/30/2017 | N/A | -28 | N/A | -23 | N/A |
6/30/2017 | N/A | -28 | N/A | -22 | N/A |
3/31/2017 | N/A | -28 | N/A | -21 | N/A |
12/31/2016 | N/A | -24 | N/A | -21 | N/A |
9/30/2016 | N/A | -24 | N/A | -21 | N/A |
6/30/2016 | N/A | -22 | N/A | -18 | N/A |
3/31/2016 | N/A | -22 | N/A | -17 | N/A |
12/31/2015 | N/A | -21 | N/A | -19 | N/A |
9/30/2015 | N/A | -20 | N/A | -20 | N/A |
6/30/2015 | N/A | -22 | N/A | -20 | N/A |
3/31/2015 | N/A | -11 | N/A | -18 | N/A |
12/31/2014 | N/A | -25 | N/A | -14 | N/A |
9/30/2014 | N/A | -25 | N/A | -11 | N/A |
6/30/2014 | N/A | -20 | N/A | -8 | N/A |
3/31/2014 | N/A | -27 | N/A | -6 | N/A |
12/31/2013 | N/A | -11 | N/A | -6 | N/A |
9/30/2013 | N/A | -8 | N/A | -6 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ATNM is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.4%).
Earnings vs Market: ATNM is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: ATNM is expected to become profitable in the next 3 years.
Revenue vs Market: ATNM's revenue (58.1% per year) is forecast to grow faster than the US market (8.2% per year).
High Growth Revenue: ATNM's revenue (58.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ATNM's Return on Equity is forecast to be high in 3 years time